Publication:


abstract

In collaboration with Genzyme, Isis Pharmaceuticals has developed Mipomersen sodium (ISIS-310312), a synthetic second-generation 20-base phosphorothioate antisense oligonucleotide (ASO) that targets messenger RNA encoding apolipoprotein B-100 (Apo B-100). Elevated cholesterol levels, in particular low-density lipoprotein cholesterol (LDL-C) which contains a single apolipoprotein B (ApoB) molecule, have been directly correlated with the incidence of cardiovascular events. Preclinical investigations in transgenic mice have demonstrated that lowering LDL-C or ApoB can reduce aortic plaque formation associated with atherosclerosis. Mipomersen pharmacokinetics showed a wide and rapid tissue distribution and a slow prolonged elimination phase of several days in a range of species. Mipomersen displayed dose-dependent efficacy in lowering LDL-C, ApoB, triglycerides, total cholesterol and other low-density lipoproteins in healthy volunteers with mild hyperlipidemia. Similar decreases were observed in patients on stable lipid-lowering therapy for familial hypercholesterolemia with baseline LDL-C levels declining towards clinically desirable concentrations of 70 mg/dL. The efficacy of mipomersen in treating patients with severe heterozygous or homozygous familial hypercholesterolemia with cardiovascular complications has been recently assessed. There have been no serious adverse events noted with treatment and mipomersen can be administered in combination with other lipid-lowering therapies. One concern noted was an elevation in liver transaminase concentrations, although these increases were reversible.

Related Articles
Review Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Expert Opin Investig Drugs. 2011
Review Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA, Hooper AJ, Burnett JR. Expert Opin Investig Drugs. 2011 Feb; 20(2):265-72. Epub 2011 Jan 6.
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Lancet. 2010
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, et al. Lancet. 2010 Mar 20; 375(9719):998-1006.
Review Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Expert Opin Pharmacother. 2010
Review Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N, Hegele RA. Expert Opin Pharmacother. 2010 Oct; 11(15):2569-72.
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Am J Cardiol. 2010
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, Kastelein JJ. Am J Cardiol. 2010 May 15; 105(10):1413-9. Epub 2010 Mar 30.
Mipomersen.
Am J Cardiovasc Drugs. 2010
Mipomersen.
. Am J Cardiovasc Drugs. 2010; 10(4):271-9.